Projects per year
Personal profile
Biography
Dr. Anderly Chüeh is a Research Fellow in the Department of Biochemistry and Molecular Biology (Monash University). Dr Chüeh specializes in cancer biomarker discovery and small molecule drug development. During his PhD in Professor KH Andy Choo’s laboratory at the Murdoch Children’s Research Institute (University of Melbourne), he developed novel 2-colour genomic tiling PCR-fragment microarray techniques for high-resolution detection of chromosomal aberrations in human patient samples – a technology that was subsequently transferred to Victorian Clinical Genetics Services (VCGS) for routine molecular diagnosis of chromosomal aberrations in human patients.
In 2009, the Ludwig Institute of Cancer Research (Melbourne Centre for Clinical Sciences) offered him a Postdoctoral Fellowship in Professor John Mariadason’s laboratory, where he mastered the different aspects of colon cancer cell biology and therapeutics. His work on histone deacetylase inhibitors (HDACi) in cancers identified a novel transcriptional axis that is predictive of HDACi drug sensitivity across tumours, defining the molecular basis for sensitivity or resistance to HDACi and established a strategy for overcoming inherent resistance to HDACi by rational combination with BCL-xL inhibitors.
Completing his postdoctoral fellowship in 2013, he joined the Walter and Eliza Hall Institute (WEHI) where he worked as a Senior Research Scientist within the Cancer Therapeutics CRC and the start-up biotech company CTx CRC Limited on industry projects, contributing to high throughput drug screening, biomarker identification and target validation on multiple drug discovery pipelines that successfully licensed novel small molecules to multinational pharmaceutical companies, including Merck and Pfizer.
In 2019, Dr Chüeh joined the laboratory of Professor Roger Daly in Monash University as a Research Fellow. Dr Chüeh’s goal is to drive to academic discoveries into clinical translation in the form of new small molecule-based cancer therapies and clinical companion biomarkers – a research vision that is facilitated by cutting-edge high-throughput screening (HTS) technologies, chemical genetics and proteomics approaches, and human genetically modified cell lines and mouse models as tools for therapeutic target validation, biomarker discovery and small molecule drug development.
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Education/Academic qualification
Human Genetics (Paediatrics), Ph.D, University of Melbourne
1 Mar 2004 → 1 Sept 2008
Award Date: 15 Dec 2008
Human Development and Disease Program (Paediatrics), B.BiomedSc Honours, University of Melbourne
3 Mar 2003 → 31 Dec 2003
Award Date: 7 Apr 2004
Biochemistry and Molecular Biology, B.BiomedSc, University of Melbourne
6 Mar 2000 → 13 Dec 2002
Award Date: 5 Mar 2003
Research area keywords
- Mitotic Signaling
- Epigenetic Enzymes
- Molecular Oncology
- Biomarkers
- Drug Discovery
- Translation Science
Collaborations and top research areas from the last five years
Projects
- 1 Active
-
Development of a precision oncology program focused on a novel therapeutic target in triple negative breast cancer
Daly, R., Chueh, A., Abud, H., Jarde, T., Loi, S., Tiganis, T., Swarbrick, A., Rosenbluh, S., Nguyen, L., Song, J. & Nekkalapudi, N.
National Breast Cancer Foundation
1/01/23 → 31/12/25
Project: Research
-
Author Correction: DUSP5 is methylated in CIMP-high colorectal cancer but is not a major regulator of intestinal cell proliferation and tumorigenesis (Scientific Reports, (2018), 8, 1, (1767), 10.1038/s41598-018-20176-9)
Tögel, L., Nightingale, R., Wu, R., Chüeh, A. C., Al-Obaidi, S., Luk, I., Dávalos-Salas, M., Chionh, F., Murone, C., Buchanan, D. D., Chatterton, Z., Sieber, O. M., Arango, D., Tebbutt, N. C., Williams, D., Dhillon, A. S. & Mariadason, J. M., Dec 2023, In: Scientific Reports. 13, 1, 2 p., 2422.Research output: Contribution to journal › Comment / Debate › Other › peer-review
Open Access -
Discovery of a highly potent, selective, orally bioavailable inhibitor of KAT6A/B histone acetyltransferases with efficacy against KAT6A-high ER+ breast cancer
Sharma, S., Chung, C. Y., Uryu, S., Petrovic, J., Cao, J., Rickard, A., Nady, N., Greasley, S., Johnson, E., Brodsky, O., Khan, S., Wang, H., Wang, Z., Zhang, Y., Tsaparikos, K., Chen, L., Mazurek, A., Lapek, J., Kung, P. P., Sutton, S., & 59 others , 19 Oct 2023, In: Cell Chemical Biology. 30, 10, p. 1191-1210 40 p.Research output: Contribution to journal › Article › Research › peer-review
Open Access19 Citations (Scopus) -
Integrative characterisation of secreted factors involved in intercellular communication between prostate epithelial or cancer cells and fibroblasts
Wu, Y., Clark, K. C., Niranjan, B., Chüeh, A. C., Horvath, L. G., Taylor, R. A. & Daly, R. J., Mar 2023, In: Molecular Oncology. 17, 3, p. 469-486 18 p.Research output: Contribution to journal › Article › Research › peer-review
Open Access7 Citations (Scopus) -
Pediatric glioma histone H3.3 K27M/G34R mutations drive abnormalities in PML nuclear bodies
Voon, H. P. J., Hii, L., Garvie, A., Udugama, M., Krug, B., Russo, C., Chüeh, A. C., Daly, R. J., Morey, A., Bell, T. D. M., Turner, S. J., Rosenbluh, J., Daniel, P., Firestein, R., Mann, J. R., Collas, P., Jabado, N. & Wong, L. H., Dec 2023, In: Genome Biology. 24, 1, 27 p., 284.Research output: Contribution to journal › Article › Research › peer-review
Open Access10 Citations (Scopus) -
Identification of biological pathways and processes regulated by NEK5 in breast epithelial cells via an integrated proteomic approach
de Castro Ferezin, C., Lim Kam Sian, T. C. C., Wu, Y., Ma, X., Chüeh, A. C., Huang, C., Schittenhelm, R. B., Kobarg, J. & Daly, R. J., Dec 2022, In: Cell Communication and Signaling. 20, 1, 15 p., 197.Research output: Contribution to journal › Article › Research › peer-review
Open Access4 Citations (Scopus)
Prizes
-
Monash Biomedicine Discovery Institute Award for Outstanding Achievement - Industry Engagement and Commercialisation Award
Chueh, Anderly (Recipient), 2023
Prize: Prize (including medals and awards)
Activities
-
National Breast Cancer Foundation (NBCF) Peer Review Committee
Anderly Chueh (Member)
2023 → …Activity: External Academic Engagement › Grant review responsibilities
-
NHMRC Development Grant Review Panel
Anderly Chueh (Member)
2020 → …Activity: External Academic Engagement › Grant review responsibilities
-
Bioscience Reports (Journal)
Anderly Chueh (Associate editor)
2018 → 2021Activity: Publication peer-review and editorial work types › Editorial responsibility
-
NHMRC Development Grant Commercial Assessor
Anderly Chueh (Reviewer)
2017 → …Activity: External Academic Engagement › Grant review responsibilities
-
Epigenomes (Journal)
Anderly Chueh (Editorial board member)
2016 → …Activity: Publication peer-review and editorial work types › Editorial responsibility